Paper Details

  1. Home
  2. Paper Details

Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.

Author: DungerDavid B, McDonaldAnna, O'SavageMartin, WilliamsRachel M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study reviewed the use of mecasermin rinfabate (iPLEX), a complex of rhIGF-I and rhIGFBP-3, for treating growth and endocrine disorders. iPLEX was developed to prolong IGF-I half-life and potentially reduce side effects.
Paper Details　
Original Abstract of the Article :
Mecasermin rinfabate (iPLEX), comprising rhIGF-I complexed to rhIGFBP-3, was developed in an attempt to prolong the half-life of IGF-I and potentially reduce side effects. It is administered as a once-daily subcutaneous injection. Treatment with rhIGF-I has been explored in a number of growth and en...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/17425255.4.3.311

データ提供：米国国立医学図書館（NLM）

Exploring Mecasermin Rinfabate: A Novel Treatment for Growth and Endocrine Disorders

The field of endocrinology is dedicated to understanding and managing hormone-related conditions. This study focuses on mecasermin rinfabate, a novel therapeutic agent comprising recombinant insulin-like growth factor I (rhIGF-I) complexed with recombinant insulin-like growth factor binding protein 3 (rhIGFBP-3). The researchers developed mecasermin rinfabate to potentially prolong the half-life of IGF-I and reduce side effects. Their research explores its potential therapeutic applications in a range of growth and endocrine disorders.

Mecasasermin Rinfabate Offers a New Approach to Treatment

The study presents mecasermin rinfabate as a promising treatment option for growth and endocrine disorders. Its unique formulation aims to address limitations of existing therapies, potentially leading to improved treatment outcomes for patients. The study highlights the innovative approaches taken in endocrinology to develop new and effective treatments for complex hormonal conditions.

A Glimpse into the Future of Endocrine Treatment

As a doctor, I'm always impressed by the advancements made in medicine. This research on mecasermin rinfabate showcases the ongoing pursuit of better treatments for endocrine disorders. The potential of this novel agent to improve the lives of patients with growth and endocrine conditions is truly inspiring. It's a reminder that the medical field is constantly evolving, bringing us closer to more effective and personalized treatment approaches.

Dr.Camel's Conclusion

The study underscores the importance of continuous research in the field of endocrinology. By developing novel therapeutic agents like mecasermin rinfabate, researchers are paving the way for more effective treatments and improved outcomes for patients with growth and endocrine disorders.

Date :
  1. Date Completed 2008-08-12
  2. Date Revised 2019-11-10
Further Info :

Pubmed ID

18363546

DOI: Digital Object Identifier

10.1517/17425255.4.3.311

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.